	Level	High	Low	*p*
n		46	46	
Age at initial pathologic diagnosis (mean (SD))		64.96 (10.28)	62.11 (11.16)	0.206
gender (%)	Female	19 (41.3)	20 (43.5)	1
	Male	27 (58.7)	26 (56.5)	
race (%)	Unknown	2 (4.3)	1 (2.2)	0.201
	Asian	4 (8.7)	0 (0.0)	
	Black or African American	1 (2.2)	1 (2.2)	
	White	39 (84.8)	44 (95.7)	
Ajcc pathologic tumor stage (%)		0 (0.0)	1 (2.2)	0.487
	Stage I	0 (0.0)	1 (2.2)	
	Stage IA	2 (4.3)	0 (0.0)	
	Stage IB	4 (8.7)	5 (10.9)	
	Stage IIA	8 (17.4)	4 (8.7)	
	Stage IIB	30 (65.2)	31 (67.4)	
	Stage III	1 (2.2)	1 (2.2)	
	Stage IV	1 (2.2)	3 (6.5)	
Clinical stage (%)		46 (100.0)	46 (100.0)	NA

Histological type (%)	Pancreas-Adenocarcinoma-Other Subtype	6 (13.0)	12 (26.1)	0.189
	Pancreas-Adenocarcinoma Ductal Type	40 (87.0)	34 (73.9)	
Histological grade (%)	G1	6 (13.0)	14 (30.4)	0.019
	G2	21 (45.7)	24 (52.2)	
	G3	19 (41.3)	8 (17.4)	
Initial pathologic dx year (mean (SD))		2011.48 (1.59)	2011.28 (1.77)	0.578
Menopause status (%)		46 (100.0)	46 (100.0)	NA
Birth days to (mean (SD))		-23919.98 (3740.05)	-22891.85 (4064.92)	0.21
Vital status (%)	Alive	19 (41.3)	37 (80.4)	<0.001
	Dead	27 (58.7)	9 (19.6)	
Tumor status (%)		6 (13.0)	4 (8.7)	0.563
	Discrepancy	0 (0.0)	1 (2.2)	
	Tumor free	16 (34.8)	20 (43.5)	
	With tumor	24 (52.2)	21 (45.7)	
Last contact days to (mean (SD))		428.68 (237.96)	722.46 (639.38)	0.059
Death days to (mean (SD))		370.78 (280.57)	547.11 (412.62)	0.157

Cause of death (%)		28 (60.9)	37 (80.4)	0.157
	Other, non-malignant disease	1 (2.2)	0 (0.0)	
	Pancreatic Cancer	16 (34.8)	9 (19.6)	
	Surgical Complications	1 (2.2)	0 (0.0)	
New tumor event type (%)		23 (50.0)	29 (63.0)	0.444
	Distant Metastasis	17 (37.0)	13 (28.3)	
	Locoregional Recurrence	5 (10.9)	3 (6.5)	
	Locoregional Recurrence|Distant Metastasis	0 (0.0)	1 (2.2)	
	New Primary Tumor	1 (2.2)	0 (0.0)	
New tumor event site (%)		23 (50.0)	31 (67.4)	0.551
	Liver	12 (26.1)	9 (19.6)	
	Lung	2 (4.3)	2 (4.3)	
	Non-regional / Distant Lymph Nodes	2 (4.3)	0 (0.0)	
	Other, specify	3 (6.5)	1 (2.2)	
	Peritoneal Surfaces	2 (4.3)	2 (4.3)	
	Tumor Bed	2 (4.3)	1 (2.2)	
New tumor event site other (%)		43 (93.5)	44 (95.7)	0.414
	Left shoulder	1 (2.2)	0 (0.0)	

	Liver	0 (0.0)	1 (2.2)	
	Omentum	1 (2.2)	0 (0.0)	
	Subcut nodule	1 (2.2)	0 (0.0)	
	Tumor Bed and Liver	0 (0.0)	1 (2.2)	
New tumor event dx days to (mean (SD))		252.26 (164.27)	497.82 (251.76)	0.001
Treatment outcome first course (%)		2 (4.3)	2 (4.3)	0.176
	Discrepancy	2 (4.3)	1 (2.2)	
	Unknown	6 (13.0)	12 (26.1)	
	Complete Remission/Response	17 (37.0)	19 (41.3)	
	Partial Remission/Response	6 (13.0)	0 (0.0)	
	Progressive Disease	12 (26.1)	10 (21.7)	
	Stable Disease	1 (2.2)	2 (4.3)	
Margin status (%)		46 (100.0)	46 (100.0)	NA
Residual tumor (%)		46 (100.0)	46 (100.0)	NA
OS (mean (SD))		0.59 (0.50)	0.20 (0.40)	<0.001
OS.time (mean (SD))		394.70 (262.61)	688.15 (601.88)	0.003
DSS (mean (SD))		0.43 (0.50)	0.20 (0.40)	0.015
DSS.time (mean (SD))		394.70 (262.61)	688.15 (601.88)	0.003

DFI (mean (SD))		0.24 (0.44)	0.37 (0.50)	0.401
DFI.time (mean (SD))		312.94 (269.80)	703.37 (416.11)	0.002
PFI (mean (SD))		0.59 (0.50)	0.41 (0.50)	0.097
PFI.time (mean (SD))		302.50 (249.66)	611.67 (547.00)	0.001
Redaction (%)		46 (100.0)	46 (100.0)	NA
Risk (%)	High	46 (100.0)	0 (0.0)	<0.001
	Low	0 (0.0)	46 (100.0)	